Abstract 2299
Background
The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context.
Methods
A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates.
Results
There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p < 0.001). The median PFS rate of patients who treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p = 0.435). The median OS of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p = 0.092). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.Table:
1464P
Patients characteristics | ||||
---|---|---|---|---|
DP (N = 102) N(%) | PP (N = 50) N(%) | EP (N = 73) N(%) | P | |
Median age | 61 | 64 | 58 | 0.038 |
Gender Male | 93(91.2) | 48(96) | 64(87.7) | 0.28 |
Histopathology Squamous cell | 53(52) | 31(62) | 43(58.9) | <0.001 |
Stage IIIB-IIIC | 65(63.7) | 31(62) | 41(56.2) | 0.59 |
Conclusions
When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdurrahman Işıkdogan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5152 - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study
Presenter: Eleonora Bergo
Session: Poster Display session 1
Resources:
Abstract
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract